Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…

Clarivate’s Epidemiology’s coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each country…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key retinal vein occlusion patient populations covering 171 countries…

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction…

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing…

Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem cell transplantation (HSCT). Steroids have been the first-line therapy for the…

The treatment of adult psoriasis represents an increasingly lucrative market for biologics for moderate to severe disease, for which conventional systemic and topical treatments are not sufficient…

Chemotherapy is the backbone of treatment for colorectal cancer, but treatment in the metastatic setting has expanded with the approval of several targeted agents. Well-established targeted…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…

As the number of approved high-cost gene therapies increases, value assessment and novel approaches to reimbursement are rapidly gaining importance. To assist developers of gene therapies in…

Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by a deficiency in factor VIII. Currently, FVIII recombinant therapies, bypass agents, Hemlibra, and vasopressin receptor…